Similar to a previous finding49, Gem-treatment of KPC mT3 PDACs increased fibroblasts, including inflammatory cancer-associated fibroblasts (iCAFs) and myofibroblastic CAFs (myCAFs), relative to the vehicle-treated group, whereas co-targeting treatment reversed the effects (Fig. 7b). The gene discussed is GEM; the disease is cancer.